Clinical Trial Update: Efficacy and Safety of Standard of Care Plus Durvalumab in Patients With Limited Disease Small Cell Lung Cancer (DOLPHIN) [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating the addition of durvalumab to standard of care in limited-stage small cell lung cancer, with reported efficacy and safety updates.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Small Cell Lung Cancer

Drugs mentioned

• Durvalumab (durvalumab)

Snippet

Sponsor: Michael Hopp | Conditions: Small Cell Lung Cancer Limited Stage | Phase 2 | Status: ACTIVE_NOT_RECRUITING